
|Videos|April 14, 2023
Understanding and Mitigating the Cardiometabolic Risks of ADT
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
4
AI system links surgical gestures with postoperative outcomes
5














